Markets in Australia curb initial setbacks during the mid-day session
The Australian market experienced a mixed day on Thursday, with the benchmark S&P/ASX 200 Index trimming early losses to close near the 8,950 level, down 4.00 points or 0.05 percent. The broader All Ordinaries Index followed suit, falling 12.20 points or 0.13 percent.
One of the day's standout performers was Qantas, with shares surging almost 9 percent. The airline reported a record profit of $2.39 billion for the full year, marking a significant increase of $316 million compared to the same period last year. In addition, Qantas declared a special dividend, adding to investors' enthusiasm.
However, not all sectors fared equally well. Shares in Telix Pharmaceuticals tumbled almost 19 percent, following the news that the FDA identified deficiencies in the Chemistry, Manufacturing, and Controls (CMC) package for Telix Pharmaceuticals' Zircaix product undergoing testing.
Other notable losses included BHP Group, down almost 1 percent, and Mineral Resources, which declined almost 4 percent. Rio Tinto also saw a drop of over 1 percent.
The weakness in iron ore miners, energy, and technology stocks was partially offset by gains in financial stocks. Shares in IDP Education, for instance, soared almost 32 percent, despite a 0.54 percent decline on Friday, September 5, 2025. The strong performance was not indicative of any particular strong positive development on that day, and no specific mention of which investors performed best was found in the data.
The challenges at Ramsay Healthcare's European hospitals business, particularly in its British mental health service Elysium, are affecting the company's performance. Shares in Ramsay Healthcare dived almost 12 percent. However, earnings for Ramsay Healthcare's Australian and UK operations remain solid.
In the currency market, the Aussie dollar was trading at $0.652 on Thursday. Meanwhile, Fortescue was one of the gainers, with shares up 1.5 percent.
Overall, the Australian market saw a day of mixed results, with Qantas' strong performance offset by the struggles of Telix Pharmaceuticals and Ramsay Healthcare, among others.
